biokine_amir

About Amir Caspi

This author has not yet filled in any details.
So far Amir Caspi has created 39 blog entries.

Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment

BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Initial results for BKT-140/BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis).

December 16th, 2013|Clinical Program BL8040|

Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference

BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference

BKT-140/BL-8040 is currently in Phase 2 study in AML patients, with partial results expected this month and final results expected in H2 2014.

December 10th, 2013|Clinical Program BL8040|

Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma

BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma

Results published in Clinical Cancer Research.

Additional clinical trial in stem cell mobilization expected to commence in H1 2014.

November 19th, 2013|Clinical Program BL8040|

BioLineRx’s BKT-140/BL-8040 Receives Orphan Drug Designation for Treatment of AML

BioLineRx’s BKT-140/BL-8040 Receives Orphan Drug Designation for Treatment of AML

September 9th, 2013|Clinical Program BL8040|

BioLineRx Announces Issuance of United States Patent

BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 for Obtaining Stem Cells

September 3rd, 2013|Clinical Program BL8040|

BioLineRx Reports Second Quarter 2013 Results

August 6th, 2013|Clinical Program BL8040|

BioLineRx Enrolls First Patient in Phase 2 Clinical Trial

BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BKT-140/BL-8040, for Treatment of Leukemia

Partial results expected in Q4 2013.

June 6th, 2013|Clinical Program BL8040|

BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting

BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting

November 7th, 2012|Clinical Program BL8040|

BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers

September 4th, 2012|Clinical Program BL8040|